# Article **Oral Iron Absorption of Ferric Citrate Hydrate and Hepcidin-25** in Hemodialysis Patients: A Prospective, Multicenter, **Observational Riona-Oral Iron Absorption Trial**

Naohisa Tomosugi <sup>1,\*</sup>, Yoshitaka Koshino <sup>2</sup>, Chie Ogawa <sup>3</sup>, Kunimi Maeda <sup>4</sup>, Noriaki Shimada <sup>5</sup>, Kimio Tomita <sup>6</sup>, Shoichiro Daimon<sup>7</sup>, Tsutomu Shikano<sup>8</sup>, Kazuyuki Ryu<sup>8</sup>, Toru Takatani<sup>9</sup>, Kazuya Sakamoto<sup>10</sup>, Satonori Ueyama <sup>11</sup>, Daisuke Nagasaku <sup>12</sup>, Masato Nakamura <sup>13</sup>, Shibun Ra <sup>14</sup>, Masataka Nishimura <sup>15</sup>, Chieko Takagi <sup>16</sup>, Yoji Ishii <sup>17</sup>, Noritoshi Kudo <sup>18</sup>, Shinsuke Takechi <sup>19</sup>, Takashi Ishizu <sup>20</sup>, Takamoto Yanagawa <sup>20</sup>, Masamichi Fukuda<sup>21</sup>, Yutaka Nitta<sup>22</sup>, Takayuki Yamaoka<sup>22</sup>, Taku Saito<sup>23</sup>, Suzuko Imayoshi<sup>23</sup>, Momoyo Omata<sup>24</sup>, Joji Oshima<sup>25</sup>, Akira Onozaki<sup>26</sup>, Hiroaki Ichihashi<sup>27</sup>, Yasuhisa Matsushima<sup>28</sup>, Hisahito Takae<sup>29</sup>, Ryoichi Nakazawa <sup>30</sup>, Koichi Ikeda <sup>31</sup>, Masato Tsuboi <sup>32</sup>, Keiko Konishi <sup>33</sup>, Shouzaburo Kato <sup>34</sup>, Maki Ooura <sup>35</sup>, Masaki Koyama <sup>36</sup>, Tsukasa Naganuma <sup>37</sup>, Makoto Ogi <sup>38</sup>, Shigeyuki Katayama <sup>39</sup>, Toshiaki Okumura <sup>40</sup>, Shigemi Kameda<sup>41</sup> and Sayuri Shirai<sup>42</sup>

- Division of Systems Bioscience for Drug Discovery, Project Research Center, Medical Research Institute, Kanazawa Medical University, Kahoku 920-0293, Ishikawa, Japan
- 2 Mizuho Hospital, Tsubata 929-0346, Ishikawa, Japan; mizuho@tiara.ocn.ne.jp
- 3 Maeda Institute of Renal Research Musashikosugi, Kawasaki 211-0063, Kanagawa, Japan; tato.ogawa@gmail.com
- 4 Maeda Institute of Renal Research Shakujii, Nerima 177-0041, Tokyo, Japan; kuni@maeda-irr.com
- 5 Tachibana Clinic, Sumida 131-0043, Tokyo, Japan; noriaki.shimada@tachibana-cl.or.jp
- 6 The Chronic Kidney Disease Research Center, Tomei Atsugi General Hospital, Atsugi 243-8571, Kanagawa, Japan; tomyw23@nifty.com
- Department of Nephrology, Daimon Clinic for Internal Medicine, Nonoichi 921-8802, Ishikawa, Japan; dai-clinic@m2.spacelan.ne.jp
- Kyoto Okamoto Memorial Hospital, Kuze 613-0034, Kyoto, Japan; sktu@okamoto-hp.or.jp (T.S.); ryu.kazuyuki@gmail.com (K.R.)
- Nephrology Division, Tojinkai Hospital, Fushimi 612-8026, Kyoto, Japan; takatani@tojinkai.jp
- 10 Department of Urology, Tomakomai Nisshou Hospital, Tomakomai 053-0803, Hokkaido, Japan; k.sakamoto@nisshou-hospital.jp
- 11 Jinaikai Ueyama Hospital, Kagoshima 890-0073, Kagoshima, Japan; s-ueyama@jin-ai-kai.or.jp 12
  - Yujin-Yamazaki Hospital, Hikone 522-0044, Shiga, Japan; nagasaku@simosaka.jp
- Susono Daiichi Clinic, Susono 410-1112, Shizuoka, Japan; susonoce@joy.ocn.ne.jp 13
- 14 Noheji Clinic, Noheji 039-3152, Aomori, Japan; kashiranodagashira@yahoo.co.jp
- 15 Shimosaka Clinic, Nagahama 526-0044, Shiga, Japan; nishimura@simosaka.jp
- 16 Ohgo Clinic, Maebashi 371-0232, Gunma, Japan; chiekot@cj8.so-net.ne.jp
- 17 Nozatomon Clinic, Himeji 670-0011, Hyogo, Japan; touseki@nozatomon.jp
- 18 Kowa Clinic, Goshogawara 037-0066, Aomori, Japan; kowa@hakuseikai.com 19
  - Takechi Clinic, Iyo 791-3141, Ehime, Japan; ikei@takechi-clinic.jp
- 20 Department of Nephrology, Tsukuba Central Hospital, Ushiku 300-1211, Ibaraki, Japan; takasi.isizu@gmail.com (T.I.); yana\_3173@yahoo.co.jp (T.Y.)
- 21 Iwakuni Medical Center, Iwakuni 740-0021, Yamaguchi, Japan; mami9380@yahoo.co.jp
- 22 The Department of Nephrology, Saiseikai Shimonoseki General Hospital, Shimonoseki 759-6603, Yamaguchi, Japan; y-nitta@simo.saiseikai.or.jp (Y.N.); simosai.jinnai.2018@gmail.com (T.Y.)
- 23 Saito Memorial Hospital, Kawaguchi 332-0034, Saitama, Japan; saitoukinen@med.email.ne.jp (T.S.); papamia888@yahoo.co.jp (S.I.)
- 24 Department of Internal Medicine, Hachioji Azumacho Clinic, Hachioji-shi 192-0082, Tokyo, Japan; m-omata@juno.ocn.ne.jp
- 25 Kubojima Clinic, Kumagaya 360-0831, Saitama, Japan; jo123kum@sakitama.or.jp
- 26 Tokatsu-Clinic Hospital, Matsudo 271-0067, Chiba, Japan; anzen.tch@mbr.nifty.com
- 27 Tokatsu Clinic Yabashira, Matsudo 270-2253, Chiba, Japan; tc-yahashira@nifty.com 28
- Tokatsu Clinic Kashiwa, Kashiwa 277-0005, Chiba, Japan; tc-kasiwa@nifty.com 29
- Tokatsu Clinic Matsudo, Matsudo 271-0077, Chiba, Japan; tc-matudo@nifty.com 30
- Tokatsu Clinic Mirai, Matsudo 271-0091, Chiba, Japan; r.nakazawa@mbr.nifty.com 31
- Tokatsu Clinic Koiwa, Edogawa 133-0056, Tokyo, Japan; tomosuginaohisa@gmail.com 32
- Kaikoukai Anjo Kyoritsu Clinic, Anjo 446-0065, Aichi, Japan; m-tsuboi@kaikou.or.jp



Citation: Tomosugi, N.; Koshino, Y.; Ogawa, C.; Maeda, K.; Shimada, N.; Tomita, K.; Daimon, S.; Shikano, T.; Ryu, K.; Takatani, T.; et al. Oral Iron Absorption of Ferric Citrate Hydrate and Hepcidin-25 in Hemodialysis Patients: A Prospective, Multicenter, Observational Riona-Oral Iron Absorption Trial. Int. J. Mol. Sci. 2023, 24, 13779. https://doi.org/10.3390/ ijms241813779

Academic Editor: Edina Pandur

Received: 15 August 2023 Revised: 27 August 2023 Accepted: 1 September 2023 Published: 7 September 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

- <sup>33</sup> Seiwa Hospital, Toyama 931-8431, Toyama, Japan; seiwakeiko7002@yahoo.co.jp
- <sup>34</sup> Nishi Interchange Clinic for Internal Medicine and Dialysis, Kanazawa 921-8001, Ishikawa, Japan; info@west-inter.or.jp
- <sup>35</sup> Maro Clinic, Tanabe 646-0004, Wakayama, Japan; maroclinic339@gmail.com
- <sup>36</sup> Nishijin Hospital, Kyoto 602-8319, Kyoto, Japan; koyama580@nisijin.net
- <sup>37</sup> Department of Nephrology, Yamanashi Prefectural Central Hospital, Kofu 400-0027, Yamanashi, Japan; naganuma-bfpn@ych.pref.yamanashi.jp
- <sup>38</sup> Department of Internal Medicine, Yuurinkouseikai Fuji Hospital, Gotemba 412-0043, Shizuoka, Japan; ogi@yuurinkouseikai.or.jp
- <sup>39</sup> Katayama Clinic, Iwakuni 741-0072, Yamaguchi, Japan; ktclinic@bronze.ocn.ne.jp
- <sup>40</sup> Mizue Yuai Clinic, Edogawa 133-0065, Tokyo, Japan; yuai@zuiko.or.jp
- <sup>41</sup> Joetsu General Hospital, Joetsu 943-8507, Niigata, Japan; kamedash@joetsu-hp.jp
- <sup>42</sup> Division of Nephrology and Hypertension, Department of Internal medicine, St. Marianna University Yokohama Seibu Hospital, Yokohama 241-0811, Kanagawa, Japan; sirababu@marianna-u.ac.jp
- Correspondence: tomosugi@kanazawa-med.ac.jp

Abstract: Oral ferric citrate hydrate (FCH) is effective for iron deficiencies in hemodialysis patients; however, how iron balance in the body affects iron absorption in the intestinal tract remains unclear. This prospective observational study (Riona-Oral Iron Absorption Trial, R-OIAT, UMIN 000031406) was conducted at 42 hemodialysis centers in Japan, wherein 268 hemodialysis patients without inflammation were enrolled and treated with a fixed amount of FCH for 6 months. We assessed the predictive value of hepcidin-25 for iron absorption and iron shift between ferritin (FTN) and red blood cells (RBCs) following FCH therapy. Serum iron changes at 2 h ( $\Delta$ Fe2h) after FCH ingestion were evaluated as iron absorption. The primary outcome was the quantitative delineation of iron variables with respect to  $\Delta$ Fe2h, and the secondary outcome was the description of the predictors of the body's iron balance. Generalized estimating equations (GEEs) were used to identify the determinants of iron absorption during each phase of FCH treatment. ΔFe2h increased when hepcidin-25 and TSAT decreased (-0.459, -0.643 to -0.276, p = 0.000; -0.648, -1.099 to -0.197, p = 0.005, respectively)in GEEs. FTN increased when RBCs decreased (-1.392, -1.749 to -1.035, p = 0.000) and hepcidin-25 increased (0.297, 0.239 to 0.355, p = 0.000). Limiting erythropoiesis to maintain hemoglobin levels induces RBC reduction in hemodialysis patients, resulting in increased hepcidin-25 and FTN levels. Hepcidin-25 production may prompt an iron shift from RBC iron to FTN iron, inhibiting iron absorption even with continued FCH intake.

Keywords: oral iron absorption; ferric citrate hydrate; hemodialysis; hepcidin-25; iron shift

#### 1. Introduction

Patients undergoing hemodialysis lose 1.5–3.0 g of iron annually due to dialysis and periodic laboratory evaluations [1], leading to iron deficiency. The oral supplementation of ferrous iron is inconvenient for iron deficiency anemia in dialysis patients due to gastrointestinal side effects [2], while the use of highly soluble ferric citrate (FC) is increasing because it has fewer side effects [3]. The long-term administration of FC increases ferritin (FTN) and transferrin saturation (TSAT), reduces intravenous iron and erythropoiesis-stimulating agent (ESA) dose requirements, and maintains hemoglobin (Hb) levels in hemodialysis patients [4–6]. Nevertheless, it remains unclear what fraction of FC is absorbed, what type of iron state promotes iron absorption, and whether long-term FC administration causes iron overload.

FTN is an index of stored iron [7], but its appropriate value in the body remains unknown. There are large differences in FTN levels in hemodialysis patients across countries, with patients in Japan and the USA having the lowest and highest FTN levels, respectively [8]. It is speculated that if a large difference exists in the amount of iron stored, there will be a difference in iron absorption regulated by hepcidin-25; however, previous FC studies have reported the same phenomena [4,5]. Yokoyama et al. [4] found that FTN essentially plateaued at week 28, increasing from 57 ng/mL at baseline to 227 ng/mL after 52 weeks, whereas ESA doses gradually decreased during this period. Moreover, Lewis et al. [5] reported that FTN levels increased from 593 ng/mL at baseline to 899 ng/mL at 52 weeks, plateauing at 6 months, while the ESA dose decreased in FC studies.

FTN correlates strongly and positively with hepcidin-25, an iron regulatory hormone, as measured using surface-enhanced laser desorption/ionization–time-of-flight mass spectrometry, liquid chromatography–tandem mass spectroscopy (LC-MS/MS), and enzyme-linked immunosorbent assay [9–11]. Thus, iron states with high FTN levels were expected to be associated with high hepcidin expression. At higher serum hepcidin-25 levels, hepcidin-25 binds to the iron exporter ferroportin (FPN) on the basolateral surface of duodenal enterocytes, thereby inducing its internalization and degradation and blocking intestinal iron absorption [12]. However, the details of this process are unclear because iron absorption and serum hepcidin-25 levels were not determined in these studies [4–6].

Moreover, whether long-term FC administration induces an iron overload remains unknown. The plateauing of FTN levels at 6 months despite continued FC administration may be related to the strict regulation and saturation of iron absorption [6]. However, in addition to the hepcidin–ferroportin axis and the erythroferrone produced during erythroblast production [13] or the guideline-based arbitrary reduction in the ESA dose that regulates red blood cell (RBC) production, no iron-regulatory metabolic mechanism is currently known. Iron metabolism is closely linked to erythropoiesis [14], and inadequate erythropoiesis may disturb iron metabolism. However, the precise mechanisms that regulate iron flow in patients undergoing hemodialysis with ESA therapy are unknown. Hence, we conducted the Riona-Oral Iron Absorption Trial (R-OIAT) using ferric citrate hydrate (FCH; Riona, Torii Pharmaceutical Co. Ltd., Tokyo, Japan) as an analytical, prospective, observational study to intercept the crosstalk between erythropoiesis and iron metabolism using intestinal iron absorption and serum hepcidin-25 as the main indices. In this study, we did not aim to supplement iron but rather to observe iron states in patients who received a fixed amount of FCH as a phosphate binder for 6 months.

#### 2. Results

### 2.1. Baseline Characteristics of the Study Participants

A total of 268 patients were included in the R-OIAT (Figure 1). Between 1 June 2017 and 1 June 2019, 584 hemodialysis patients using FCH as a phosphate binder were enrolled in the R-OIAT. According to the exclusion criteria, 213 and 78 participants were excluded at 3 months (M3) and 6 months (M6), respectively. The numbers of patients with a serum C-reactive protein (CRP) level > 0.5 mg/dL at baseline (M0), M3, and M6 were 103, 37, and 25, respectively. Finally, 268 patients who continued to receive a fixed amount of FCH for 6 months were analyzed. The trial concluded in June 2020. The baseline characteristics of the participants are shown in Table 1. The mean age of the participants was 63.0 years (SD, 11.7), 57% of patients were male, 55.6% received 750 mg of FCH, and 49.6% were injected with darbepoetin alfa.

Table 1. Baseline characteristics of R-OIAT participants.

63.0 (11.6)
63.8 (11.3), 153 (57%)
62.0 (12.0), 115 (43%)
149 (55.6%)
101 (37.7%)
18 (6.7%)
40 (14.9%)
133 (49.6%)
65 (24.3%) 30 (11.2%)

Data are mean (SD) or *n* (%). FCH, ferric citrate hydrate; ESA, erythropoiesis-stimulating agent.




Figure 1. Flow chart depicting the study's population selection.

#### 2.2. Association of Changes in Clinical Indices at Different 3-Month Intervals

The clinical measurements on the day of R-OIAT testing at M0, M3, and M6 are summarized in Table 2. FTN levels increased significantly from 100.7 ng/mL at baseline to 116.7 ng/mL at 24 weeks, while the ESA dose decreased, and Hb concentrations remained stable. The effects of the amount of FCH on the changes in iron absorption ( $\Delta$ Fe2h) and iron variables for 6 months are shown in Table 3. In patients receiving 750 mg (n = 149), 1500 mg (n = 101), or 2250 mg (n = 18) of FCH, no significant interaction between the amount of FCH and the exposure time was observed for all iron variables; this means that three independent groups changed similarly to each other with respect to time (Table 3). Although  $\Delta$ Fe2h levels were significantly lower in the low-dose group than in the high-dose group, the differences remained mostly unchanged throughout the 6 months. FTN and hepcidin-25 levels were significantly lower in the low-dose group than in the high-dose group at M0, and the difference was maintained at M3 and M6. In each group, there was a significant increase in FTN, Hb, MCH, and TSAT levels over 6 months. When RBCs  $\leq 350 \times 10^4$  /µL, the number of cases with Hb exceeding 12 g/dL was only two (0.7%).

#### 2.3. Association of $\Delta$ Fe2h with Iron Variables

Generalized estimating equations (GEEs) were used to identify the determinants of  $\Delta$ Fe2h during each phase of FCH treatment: M0, M3, and M6.  $\Delta$ Fe2h was affected by hepcidin-25 and TSAT (Table 4). Log  $\Delta$ Fe2h increased by 0.459 µg/dL per 1 ng/mL decrease in Log hepcidin-25 [95% CI: -0.643 to -0.276, *p* = 0.000] and increased by 0.648 µg/dL per 1 % decrease in Log TSAT [95% CI: -1.099 to -0.197, *p* = 0.005]. Hb levels were excluded because of collinearity with respect to RBCs based on the formula Hb = RBC × MCH. In the three datasets of iron markers per patient at M0, M3, and M6 (*n* = 804), there were significant negative correlations of  $\Delta$ Fe2h with hepcidin-25 (r = -0.163, *p* = 0.000, Figure 2A) and TSAT (r = -0.149, *p* = 0.000, Figure 2B).

	Baseline M0 ( <i>n</i> = 268)		3 Months M3 ( <i>n</i> = 268)		6 Months M6 ( <i>n</i> = 268)			
	Mean	(SD)	Mean	(SD)	Mean	(SD)	р	
ESA, IU/week	3679.3	(3406.8)	3256.1	(3205.9)	3147.7	(3026.6)	0.000	
RBCs, $10^4/\mu L$	360.3	(44.5)	364.9	(48.4)	360.9	(45.5)	0.301	
Hb, g/dL	11.2	(1.2)	11.4	(1.3)	11.4	(1.2)	0.019	
Ht, %	34.6	(3.8)	35.1	(4.0)	34.9	(3.6)	0.162	
MCV	95.8	(8.8)	96.6	(5.5)	96.6	(7.5)	0.301	
MCH, pg/cell	31.2	(2.2)	31.5	(2.1)	31.7	(2.0)	0.000	
Plat, $10^4/\mu L$	19.2	(5.9)	20.1	(14.8)	18.8	(6.1)	0.018	
S-Fe, μg/dL	65.7	(26.2)	70.3	(28.4)	69.8	(27.8)	0.013	
FTN, ng/mL	100.7	(93.2)	108.9	(99.6)	116.7	(102.7)	0.000	
TSAŤ, %	27.4	(11.6)	28.9	(12.0)	29.5	(12.5)	0.009	
Hepcidin-25, ng/mL	42.9	(38.7)	50.5	(41.6)	45.6	(35.6)	0.000	
$\Delta$ Fe2h, µg/dL	26.6	(37.2)	24.7	(35.8)	22.9	(32.3)	0.062	
P, mg/dL	5.5	(1.3)	5.5	(1.3)	5.5	(1.3)	0.982	
Albumin, g/dL	3.9	(3.4)	4.1	(4.1)	3.9	(3.5)	0.127	
AST, IU/L	13.5	(6.7)	13.8	(6.3)	13.9	(7.8)	0.663	
ALT, IU/L	11.4	(5.4)	11.9	(7.6)	12.2	(9.4)	0.898	
Al-P, IU/mL	239.5	(110.5)	241.7	(110.2)	238	(111.6)	0.134	
γ-GTP, IU/L	21.3	(21.0)	20.7	(17.0)	22.2	(25.0)	0.455	

Table 2. Characteristics of participants and iron status at the time of the iron absorption test.

The obtained data are expressed as the mean  $\pm$  standard deviation (SD). A one-way repeated measures analysis of variance (ANOVA) was used for the comparison of data at M0, M3, and M6. The statistical significance was set at p < 0.05. ESA, erythropoiesis-stimulating agent; RBCs, red blood cells; Hb, hemoglobin; Ht, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; S-Fe, serum iron; FTN, ferritin; TSAT, transferrin saturation;  $\Delta$ Fe2h, iron absorption in 2 h; P, phosphate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Al-P, alkaline phosphatase; GTP, glutamyl transpeptidase.

**Table 3.** Effects of the amount of FCH on the changes in iron absorption and iron variables for 6 months.


Iron Variable		Time Course						F		
	FCH (mg)	M	)	N	13		M6	FCH	Time	Interaction
	0							Amounts	Course	Effects
$\Delta$ Fe2h, µg/dL	750 1500 2250	23.0 29.9 25.6	(37.5) (37.1) (44.9)	18.5 29.6 27.8	(36.6) (35.3) (50.2)	17.2 29.1 21.2	(28.0) (36.2) (46.5)	7.58 *	2.42	0.35
FTN, ng/mL	750 1500 2250	72.8 136.7 129.4	(72.0) (103.8) (112.3)	81.3 147.9 118.6	(70.4) (120.8) (105.2)	84.5 160.3 139.2	(78.0) (114.4) (121.8)	22.02 **	7.92 *	0.168
Hepcidin-25, ng/mL	750 1500 2250	33.9 53.8 56.4	(32.2) (43.1) (44.7)	41.1 63.0 58.9	(32.8) (49.6) (39.5)	36.6 54.7 68.8	(24.5) (41.9) (51.2)	8.23 **	5.66 *	0.78
TSAT, %	750 1500 2250	26.5 28.4 28.3	(11.5) (11.7) (12.1)	29.1 28.4 30.1	(12.5) (11.2) (12.2)	28.7 29.9 32.8	(11.2) (13.6) (15.4)	0.52	5.13 *	0.60
RBCs, 10 <sup>4</sup> /µL	750 1500 2250	360.3 365.3 332.3	(42.5) (44.9) (50.3)	361.2 372.5 353.8	(47.6) (48.7) (50.9)	358.2 368.7 339.8	(44.9) (42.5) (58.8)	5.29 *	0.38	0.71
Hb,g/dL	750 1500 2250	11.2 11.4 10.6	(1.1) (1.2) (1.5)	11.3 11.6 11.3	(1.2) (1.4) (1.4)	11.3 11.6 11.1	(1.2) (1.1) (1.5)	4.63 *	5.87 *	0.73
MCH, pg/cell	750 1500 2250	31.1 31.2 32.1	(2.3) (2.0) (2.0)	31.5 31.4 32.2	(2.2) (1.8) (2.5)	31.6 31.6 32.3	(2.2) (1.8) (2.0)	1.31	9.85 *	0.91
ESA, IU/week	750 1500 2250	3701 3606 3902	(3318) (3477) (3901)	3231 3092 4375	(3367) (2738) (4134)	3015 3096 4527	(3031) (2773) (4052)	1.36	0.77	3.20

The obtained data are expressed as the mean  $\pm$  standard deviation (SD). A two-way (amount  $\times$  time) repeated measures ANOVA was used for the comparison of the data at M0, M3, and M6. When a significant difference was detected, a multiple comparison test was performed using the post hoc Bonferroni correction. The statistical significance was set at p < 0.05. FCH = 750 mg (n = 149); FCH = 1500 mg (n = 101); FCH 2250 mg (n = 18). FCH, ferric citrate hydrate;  $\Delta$ Fe2h, iron absorption in 2 h; FTN, ferritin; TSAT, transferrin saturation; RBCs, red blood cells; Hb, hemoglobin; MCH, mean corpuscular hemoglobin; ESA, erythropoiesis-stimulating agent. \* p < 0.05. \*\* p < 0.001.

Parameter Estimates					
Variables	Log ΔFe2	h, μg/dL	95%	<b>X7.1</b>	
	В	SE	Lower	Upper	<i>p</i> Value
hepcidn-25, ng/mL	-0.459	0.094	-0.643	-0.276	0.000
$RBCs, 10^4/\mu L$	0.989	0.719	-0.421	2.398	0.169
MCH, pg/cell	-1.220	1.582	-4.321	1.882	0.441
TSAT, %	-0.648	0.230	-1.099	-0.197	0.005
FTN, ng/mL	0.099	0.133	-0.161	0.359	0.457
ESA, IU/week	-0.188	0.121	-0.426	0.049	0.120
FCH, 750 mg	0.005	0.218	-0.431	0.422	0.983
FCH, 1500 mg	0.376	0.213	-0.041	0.794	0.077
FCH, 2250 mg	0 a				
age	0.005	0.004	-0.002	0.013	0.155
sex, female	0.041	0.088	-0.131	0.214	0.637
sex, male	0 <sup>a</sup>				

**Table 4.** Predictors for  $\Delta$ Fe2h.

<sup>a</sup> This parameter is redundant and is set to 0.  $\Delta$ Fe2h, iron absorption in 2 h; RBCs, red blood cells; MCH, mean corpuscular hemoglobin; TSAT, transferrin saturation; FTN, ferritin; ESA, erythropoiesis-stimulating agent; FCH, ferric citrate hydrate.



**Figure 2.** Correlation between  $\Delta$ Fe2h and hepcidin-25 and TSAT. Correlation between  $\Delta$ Fe2h and hepcidin-25 (**A**) and TSAT (**B**). The data included all samples from 268 patients at M0, M3, and M6 during FCH therapy for 6 months (black dots, *n* = 804).  $\Delta$ Fe2h, iron absorption; MCH, mean corpuscular hemoglobin.  $\Delta$ Fe2h, iron absorption in 2 h; TSAT, transferrin saturation.


#### 2.4. Association of Hepcidin-25 with Iron Variables

Predictors for hepcidin-25 were analyzed via GEEs using iron variables, excluding  $\Delta$ Fe2h (Table 5). Hepcidin-25 was affected by RBC, MCH, TSAT, FTN, and ESA. Log hepcidin-25 decreased by 0.790 ng/mL per 1 × 10<sup>4</sup>/µL decrease in Log RBC [95% CI: 0.178 to 1.401, *p* = 0.011]; by 1.667 ng/mL per 1 pg/cell decrease in Log MCH [95% CI: 0.121 to 3.213, *p* = 0.035]; by 0.372 ng/mL per 1 % decrease in Log TSAT [95% CI: 0.144 to 0.600, *p* = 0.001]; by 0.754 ng/mL per 1 ng/mL decrease in Log FTN [95% CI: 0.637 to 0.871, *p* = 0.000]; and by 0.353 ng/mL per 1 IU/week increase in Log ESA [95% CI: -0.462 to -0.245, *p* = 0.000]. In the three datasets of iron markers per patient at M0, M3, and M6 (*n* = 804), there were significant correlations between hepcidin-25 and ESA (r = 0.201, *p* = 0.000, Figure 3A), FTN (r = 0.646, *p* = 0.000, Figure 3B), and TSAT (r = 0.278, *p* =0.000, Figure 3D). An increase in FTN up to 100 ng/mL was accompanied by an increase in hepcidin-25, but even if FTN increased beyond that level, no increase in hepcidin-25 was observed, as if there was an upper limit for hepcidin expression. MCH had no significant correlations with hepcidin-25 (r = 0.065, *p* = 0.063, Figure 3C).

**Parameter Estimates** Log Hepcidin-25, Log Ferritin, 95% CI 95% CI ng/mL p Value p Value ng/mL В в SE SE Variables Lower Upper Lower Upper 0.030 hepcidin-25, ng/mL 0.297 0.239 0.355 0.000 0.871 0.7540.0600.637 0.000 FTN, ng/mL -1.0350.000 RBC,  $10^4/\mu L$ 0.790 0.312 0.178 1.401 0.011 -1.3920.182 -1.749MCH, pg/cell TSAT, % 1.667 0.789 0.121 3.213 0.035 0.858 0.514 -0.1501.866 0.095 0.372 0.1160.144 0.600 0.001 0.233 0.068 0.099 0.3670.001 ESA, IU/week  $-0.462 \\ -0.252$ -0.172-0.3530.055 -0.2450.000 -0.0840.045 0.005 0.064FCH, 750 mg 0.056 0.031 -0.1410.012 0.068 -0.2340.031 0.135 -0.101FCH, 1500 mg -0.1440.061 -0.263-0.0260.017 0.131 0.072 -0.0090.270 0.067 0 <sup>a</sup> 0 <sup>a</sup> FCH, 2250 mg 0.000 0.001 -0.002 0.003 0.773 0.000 0.0015 -0.0030.003 0.798 age sex, female 0.130 0.036 0.060 0.200 0 -0.0370.033 -0.1010.028 0.263 sex, male 0 a 0 a

Table 5. Predictors for hepcidin-25 and FTN.


<sup>a</sup> This parameter is redundant and is set to 0. RBC, Red blood cell; MCH, mean corpuscular hemoglobin; TSAT, transferrin saturation; FTN, ferritin; ESA, erythropoiesis-stimulating agent; FCH, ferric citrate hydrate.



**Figure 3.** Correlation between hepcidin-25 and iron markers. Correlation between hepcidin-25 and ESA (**A**), FTN (**B**), MCH (**C**), and TSAT (**D**). Data included all samples from 268 patients at M0, M3, and M6 during FCH therapy for 6 months (block dots, n = 804). ESA, erythropoiesis-stimulating agent; FTN, ferritin; MCH, mean corpuscular hemoglobin; TSAT, transferrin saturation.


#### 2.5. Patterns of FTN Fluctuations

Contrary to expectations, because FTN did not necessarily increase gradually with the continuous administration of FCH, the fluctuation pattern of FTN was analyzed. Patients were classified into four groups based on 3-month changes in FTN from M0 to M3 or from M3 to M6 (denoted as  $\Delta$ FTN<sub>M3-M0</sub> and  $\Delta$ FTN<sub>M6-M3</sub>, respectively): P-1 ( $\Delta$ FTN<sub>M3-M0</sub>: positive;  $\Delta$ FTN<sub>M6-M3</sub>: positive; n = 63), P-2 ( $\Delta$ FTN<sub>M3-M0</sub>: positive;  $\Delta$ FTN<sub>M6-M3</sub>: negative; n = 84), P-3 ( $\Delta$ FTN<sub>M3-M0</sub>: negative;  $\Delta$ FTN<sub>M6-M3</sub>: negative; n = 37). FTN gradually increased only in 63 cases (23.5%) during both 3-month intervals (Figure 4) and gradually decreased in 37 cases (13.8%). Interestingly, an increase in FTN corresponded to a significant decrease in RBCs and Hb and vice versa with the mirror image in each group. Moreover, there was a significant negative correlation between  $\Delta$ FTN<sub>M3-M0</sub> was positive were negative with respect to  $\Delta$ FTN<sub>M6-M3</sub>, and 84 of 121 patients (69.4%) whose  $\Delta$ FTN<sub>M3-M0</sub> was negative were observed between the



changes in the first and second 3-month periods with respect to hepcidin-25, Hb, and RBCs (r = 0.527, 0.589, and 0.599, respectively; Figure 5B–D).

**Figure 4.** Changes in FTN and iron variables every three months (n = 268). Patients were classified into four groups based on 3-month changes in FTN from M0 to M3 or from M3 to M6 (denoted as  $\Delta$ FTN<sub>M3-M0</sub> and  $\Delta$ FTN<sub>M6-M3</sub>, respectively); P-1 ( $\Delta$ FTN<sub>M3-M0</sub>: positive;  $\Delta$ FTN<sub>M6-M3</sub>: positive; n = 63), P-2 ( $\Delta$ FTN<sub>M3-M0</sub>: positive;  $\Delta$ FTN<sub>M6-M3</sub>: negative; n = 84), P-3 ( $\Delta$ FTN<sub>M3-M0</sub>: negative;  $\Delta$ FTN<sub>M6-M3</sub>: positive;  $\Delta$ FTN<sub>M6-M3</sub>: positive; n = 84), and P-4 ( $\Delta$ FTN<sub>M3-M0</sub>: negative;  $\Delta$ FTN<sub>M6-M3</sub>: negative; n = 37). FTN, Ferritin; RBCs, red blood cells; Hb, hemoglobin; MCH, mean corpuscular hemoglobin. Data are shown as means  $\pm$  SEM of samples. The levels of iron variables at M0 were compared with those at M3 and M6. \* p < 0.05. \*\* p < 0.001.




**Figure 5.** Inverse correlations between the changes in iron variables from M0 to M3 and those from M3 to M6 (black dots, n = 268). (**A**):  $\Delta$ FTN<sub>M3-M0</sub> vs.  $\Delta$ FTN<sub>M6-M3</sub>; (**B**):  $\Delta$ RBC<sub>M3-M0</sub> vs.  $\Delta$ RBC<sub>M6-M3</sub>; (**C**):  $\Delta$ Hb<sub>M3-M0</sub> vs.  $\Delta$ Hb<sub>M6-M3</sub>; (**D**):  $\Delta$ HEP<sub>M3-M0</sub> vs.  $\Delta$ hepcidin-25<sub>M6-M3</sub>. Only 63 cases (23.5%) were positive for both  $\Delta$ FTN<sub>M3-M0</sub> and  $\Delta$  FTN<sub>M6-M3</sub>.  $\Delta$ <sub>M3-M0</sub>: Changes from M0 to M3;  $\Delta$ <sub>M6-M3</sub>: changes from M3 to M6. FTN, ferritin; Hb, hemoglobin; RBCs, red blood cells. The blue dotted line describes the regression line.

# 2.6. Background of Changes in FTN

Predictors for FTN were also analyzed via GEEs using iron variables, excluding  $\Delta$ Fe2h (Table 5). FTN was affected by hepcidin-25, RBC, and TSAT. Log FTN increased by 0.297 ng/mL per 1 ng/mL increase in Log hepcidin-25 [95% CI: 0.239 to 0.355, *p* = 0.000]; by 1.392 ng/mL per 1 × 10<sup>4</sup>/µL decrease in Log RBCs [95% CI: -1.749 to -1.035, *p* = 0.000]; and by 0.233 ng/mL per 1 % increase in Log TSAT [95% CI: 0.099 to 0.367, *p* = 0.001].

To analyze the effect of the change in RBCs counts on FTN values over 3 months, the levels at M0 and M3 were treated as starting points for the first and second 3-month periods, and levels at M3 and M6 were treated as 3-month points, respectively. Two datasets of iron variables were evaluated equally, and the changes in iron variables over 3 months were represented as  $\Delta_{3M}$  (n = 536). Each datum was classified into four groups, G-1, G-2, G-3, or G-4, according to the RBC value at start points M0 or M3; RBC  $\leq$  300: 300 < RBC  $\leq$  350, 350 < RBC  $\leq$  400, and RBC > 400 × 10<sup>4</sup>/µL, respectively. Furthermore, each case was classified into G-a when each  $\Delta$ RBC<sub>3M</sub> was negative and into G-b when  $\Delta$ RBC<sub>3M</sub> was positive. The start and end points were vectorized as the mean values of MCH and RBCs (Figure 6A). In any RBC region, changes in FTN for 3 months in each group decreased in the increased RBC group (b) and increased in the decreased RBC group (a) (Figure 6B).



**Figure 6.** Effects of RBCs on changes in FTN. To analyze the effect of the change in RBC counts on FTN values over 3 months, the levels at M0 and M3 were treated as starting points for the first and second 3-month periods, and levels at M3 and M6 were treated as 3-month points, respectively. Two datasets of iron variables were evaluated equally, and the changes in iron variables over 3 months were represented as  $\Delta_{3M}$  (n = 536). Each case was classified into 4 groups, G-1, G-2, G-3, and G-4, according to the RBC value at start points (M0 and M3): RBC  $\leq$  300, 300 < RBC  $\leq$  350, 350 < RBC  $\leq$  400 and RBC > 400  $\times$  10<sup>4</sup>/µL, respectively. Furthermore, each case was classified into G-a when each  $\Delta$ RBC<sub>3M</sub> was negative and G-b when positive. (**A**) The start and end points were vectorized as the mean values of MCH and RBCs. Hb 10g/dL-line (blue) and Hb 12g/dL-line (red) are shown based on the formula Hb = RBC  $\times$  MCH. (**B**) The levels of  $\Delta$ FTN<sub>3M</sub> were presented in each group. Data are shown as mean  $\pm$  SEM of samples. RBCs, red blood cells; MCH, mean corpuscular hemoglobin; Hb, hemoglobin; FTN, ferritin. The levels of G-a were compared with those of G-b. \* p < 0.05.

# 3. Discussion

The features of this study are that participants were taking a fixed amount of FCH without changing the dose for 6 months and had no inflammation that affected hepcidin-25 expression via IL6R [15]. Under these conditions, hepcidin-25 and TSAT were the strongest inverse explanatory factors for intestinal iron absorption based on GEEs. At the molecular level, hepcidin-25 has been shown to control the distribution density of FPN on the cell membrane's surface [16] and intestinal divalent metal-iron transporter 1 expression [17], leading to the influx of iron from intestinal epithelial cells into the blood. More recently, Hanudel et al. [18] demonstrated that intestinal ferric citrate absorption relies on conventional enterocyte iron transport by ferroportin, without significant paracellular absorption, using Tmprss6 and FPN knockout mice. The results of this study reconfirmed that the clinical measurement of hepcidin-25 would be a great tool for estimating iron absorption in clinical practice as well. Similar phenomena may also be observed in hepatocytes and macrophages, which bear FPN on membranes [19].


MCH and TSAT were explanatory factors for hepcidin-25. MCH is calculated by dividing Hb by RBCs and indicates the average amount of Hb, including in one RBC. MCH has an upper limit of 33 [20,21], up to which erythroblasts can take up iron for Hb synthesis; thus, MCH could be taken as an indicator of iron storage capacity in RBCs. It is speculated that when the level of MCH is low—which means that there are large reserve-iron storage capacities in RBCs—serum iron may be readily supplied to erythroblasts, its concentration may decrease and iron absorption from the intestinal tract would increase to replenish it. Erythroblasts require large amounts of iron for hemoglobin synthesis; therefore, they express very high levels of TfR1 [22]. Although MCH has received less attention in the assessment of iron metabolism, it could be used to infer the reserve storage capacity of iron in the RBCs.

FTN was not an explanatory factor of iron absorption, although Eshbach et al. [23] reported that food iron absorption increases when the FTN serum is below 30 ng/mL and decreases when there is more than 100 ng/mL by evaluating total body isotope activity at 2 weeks after the ingestion of the extrinsic tag of radioiron salt added to a meal. Since the amount of iron in the blood is as low as 2–3 mg [24], it is speculated that a decrease in serum iron concentration and hepcidin-25 due to rapid iron consumption by erythropoiesis after ESA administration [25] may occur regardless of the value of stored FTN iron. Given that FPN is currently the only known iron transporter, the rapid decrease in hepcidin-25 levels after ESA administration in hemodialysis patients, which means the expansion of erythropoiesis, may be immensely advantageous for iron absorption in the intestine.


ESA and FTN were explanatory factors for hepcidin-25 in addition to TSAT, which is an index of serum iron concentrations that stimulates TfR2 in hepatocytes to induce the expression of hepcidin [26]. In our previous study [10], serum iron, hepcidin-25, and FTN levels rapidly decreased after ESA administration and then recovered during the interval for the next ESA administration. Chaston et al. [16] reported that the FPN response to hepcidin-25 differs among cells, e.g., reticuloendothelial macrophages, hepatocytes, and enterocytes, and that a rapid increase in hepcidin-25 reduces macrophage FPN expression after 2 h, but enterocyte FPN reduction appears only when hepcidin-25 levels have remained continuously high for 24 h. These phenomena may be responsible for the complicated relationship between iron absorption and hepcidin-25, and these reactions cannot be captured using one-time measurements. Time-course measurements should be included in future studies.

In the present study, the predictors of FNT were analyzed using GEEs because FTN has often been used to assess the body's iron stores [27]. Hepcidin-25 is a positive predictor, and RBCs and ESA are negative predictors of FTN. These findings may be due to the arbitrary adjustment of ESA such that Hb could be maintained at 10–12 g/dL according to clinical guidelines [28,29]. Approximately 80% of the body's iron is found in RBCs [30], with 90% of daily iron consumption used by erythroblasts to synthesize Hb [31]. The erythroid system maintains iron homeostasis as an iron reservoir [31] whereby iron is conserved and recycled

in the body [32]. In a closed iron metabolism system, limiting erythropoiesis by reducing ESA doses could induce an increase in serum iron, followed by hepcidin-25; inhibit the delivery of iron to the blood by macrophages; and concomitantly suppress intestinal iron absorption. As a result, FTN increases in macrophages phagocytized senescent erythrocytes. This phenomenon appears to be a shift from erythrocyte iron to FTN iron or vice vers (Figure 7). Our findings provide insight into the reasons why the rate of increase in FTN is reduced at 24 weeks and why it reaches a plateau despite continuous FC exposure for 52 weeks [4–6]. When the Hb level is  $\geq$ 12 g/dL, ESA is arbitrarily reduced, and Hb levels are adjusted between 10 and 12 g/dL according to the guidelines. As shown in Figure 8, the Hb level, which was 13 g/dL in RBCs  $450 \times 10^4 / \mu$ L (MCH 28.9 pg, point A), was reduced to 11.6 g/dL when reducing ESA and resetting RBCs to  $400 \times 10^4/\mu$ L (point B). During this period, the FTN level increased because the RBC iron capacity decreased, and the corresponding amount of iron shifted to FTN iron. When FCH administration continued, MCH increased with iron absorption, and Hb levels easily exceeded 12 g/dL (RBCs to  $400 \times 10^4$ /µL, MCH 32.5 pg, point C). If ESA was reduced again and RBCs reset to  $350 \times 10^4/\mu$ L, the Hb level improved to 11.4 g/dL (point D) with another increase in the FTN level. When RBC is  $\leq 350 \times 10^4 / \mu L$ , there is little risk of Hb being  $\geq 12 \text{ g/dL}$ even if FCH therapy is continued because there is an upper limit against MCH, which falls normally within the range of 27–33 pg [20,21]. At this stage, there is no need to further reduce the ESA, and the FTN reaches a plateau without increasing. Such a series of reactions may occur regardless of the FTN value at baseline, such as 227 ng/mL in Japan and 899 ng/mL in the United States [4-6]. Our concern with FCH therapy is whether the long-term use of FC may cause iron overload. These findings suggest that initially setting RBC to 300–350  $\times$   $10^4/\mu L$  followed by oral iron supplementation, in which Hb levels do not exceed 12 g/dL, would minimize fluctuations in FTN. Whether such a procedure could reduce the requirement for ESA and prevent iron overload should be clarified in future studies.



**Figure 7.** Model of crosstalk between the erythropoietic system and iron metabolic system. The stimulation of erythropoiesis by ESA is a trigger for crosstalk. When ESA stimulates hematopoiesis (**A**), serum iron is rapidly consumed and decreases. This triggers a decrease in the expression of hepcidin-25. Iron is then supplied from iron-store cells via FPN. If the supply of iron recovered from senescent red blood cells alone is inadequate, stored iron is consumed. This phenomenon appears to be a shift from FTN iron to RBC iron. In this situation, iron is readily absorbed from the intestinal tract. When erythropoiesis decreases due to the limitation of ESA (**B**), serum iron increases because of reduced iron consumption in bone marrow, and hepcidin-25 also increases. As a result, the iron supply to blood is suppressed, and unsupplied iron is stored in cells. Iron recovered from senescent red blood cells is also stored. This appears to be a shift from RBC iron to FTN iron. In this situation, iron absorption from the intestinal tract is suppressed. FTN, ferritin; ESA, erythropoiesis-stimulating agent; RBCs, red blood cells.



**Figure 8.** Hypothesis of Hb adjustment shown in the RBC/MCH diagram during FCH therapy. When the Hb level is  $\geq 12$  g/dL, ESA is arbitrarily reduced, and Hb levels are adjusted between 10 and 12 g/dL according to the guidelines. Hb level, which was 13 g/dL in RBC 450  $\times 10^4$ /µL (MCH 28.9 pg, point A), was reduced to 11.6 g/dL when reducing ESA and resetting RBCs to  $400 \times 10^4$ /µL (point B). During this period, the FTN level increased because RBC iron's capacity decreased, and the corresponding amount of iron shifted to FTN iron. When FCH administration was continued, MCH increased with iron absorption, and Hb levels easily exceeded 12 g/dL (RBC to  $400 \times 10^4$ /µL, MCH 32.5 pg, point C). If ESA was reduced again and RBCs reset to  $350 \times 10^4$ /µL, Hb levels improved to 11.4 g/dL (point D) with another increase in the FTN level. When RBCs are  $\leq 350 \times 10^4$ /µL, there is little risk of Hb being  $\geq 12$  g/dL even if FCH therapy is continued because there is an upper limit against MCH, which falls normally within the range of 27–33 pg. At this stage, there is no need to further reduce the ESA, and FTN reaches a plateau without increasing. Hb, hemoglobin; RBCs, red blood cells; MCH, mean corpuscular hemoglobin; FCH, ferric citrate hydrate; ESA, erythropoiesis-stimulating agent.

The upper limit of hepcidin-25 production in terms of the relationship with FTN has not been reported previously. We showed that the physiological concentrations of hepcidin-25 have an upper limit of more than 100 ng/mL FTN. Similar trends have been observed in myelodysplastic syndromes [33], thalassemia [34], and dialysis patients [35], but there is no description of the upper limit of hepcidin in these papers. When the cellular labile iron pool (LIP) increases, FTN expression is stimulated via iron-responsive elements and iron regulatory proteins at the translational level, and the ferrous iron of LIP is mobilized to FTN as ferric iron to reduce the risk of radical developments in the cytoplasm [7]. On the other hand, elevated LIP enhances the expression of bone morphogenetic protein 6 (BMP6) in hepatic non-parenchymal cells, which binds to the hepatocyte BMP receptor in paracrine and stimulates hepcidin expression via the BMP6/SMAD pathway to prevent iron export via FPN to blood [36]. If it is hypothesized that there is an upper limit on the levels of LIP to prevent the cytoplasm from radical exposure, BMP6 and hepcidin-25 in its downstream will also have an upper limit, and their serum levels will fluctuate according to LIP. When FTN remains undegraded in the cytoplasm, the levels of FTN might increase cumulatively without an upper limit. In myelodysplastic syndromes, patients with more than 10,000 ng/mL of FTN were reported [37]. Hepcidin-25 may be a predictor of LIP and BMP6, and cumulative increases in FTN may indicate that the LIP has repeatedly reached the upper limit. This may be the reason why FC was effective regardless of the FTN levels in previous studies [4-6]. Although we only targeted cases without inflammation, the

difference in hepcidin synthesis via STAT3 stimulated by IL-6 during inflammation should be examined in future studies [32].

In conclusion, our data suggested that a key molecule for facilitating the crosstalk between hematopoietic and iron metabolic systems in order to keep the balance between iron consumption in serum and iron supplies to serum was hepcidin-25, and ESA was shown to be a trigger that causes a shift in iron between the body's stored iron and stored RBC iron. Limited erythropoiesis was one of the causes of FTN increases in hemodialysis patients undergoing FCH therapy, in addition to iron absorption from the intestinal tract. A major factor altering iron-related factors in dialysis patients may be the fluctuation of RBCs, which have large capacities for iron storage. If the RBC count is maintained below  $350 \times 10^4/\mu$ L, iron overload would not occur even with a sustained oral supply of iron. Although our results do not provide evidence for an adequate RBC number, our study provides a basis for clinical trials with respect to evaluating RBC-restricting strategies to minimize the ESA dose and improve iron metabolism in patients with renal anemia.

#### 4. Materials and Methods

# 4.1. Study Design and Data Sources

The R-OIAT recruited patients from 42 hemodialysis centers in Japan. Eligible subjects (n = 584) were adult patients with end-stage renal disease who were on hemodialysis three times per week for at least one month before the R-OIAT trial and who were prescribed 750 mg–2250 mg doses of FCH as a phosphate binder. Eligible hemodialysis patients were not pregnant and had no malignancies or infections. Patients were excluded if they received intravenous iron supplementation and blood transfusion, were transferred to a different clinic, ceased using FCH, changed FCH dosage, or had inflammation (CRP level > 0.5 mg/dL). Finally, 268 individuals who received a fixed amount of FCH as a phosphate binder for 6 months were enrolled: 750 mg (n = 149), 1500 mg (n = 101), and 2250 mg (n = 18). This study was conducted in accordance with the Declaration of Helsinki and approved by the Kanazawa Medical University Ethics Committee (No. M401). All participants provided written informed consent.

## 4.2. Procedures

The patients received FCH three times a day after meals. One tablet of FCH (250 mg) contains approximately 60 mg of ferric iron. The participants consumed their regular diets during the study period. Thus, on the day of the R-OIAT, blood was drawn early in dialysis, and patients received one-third of the total daily FCH dose shortly thereafter. After 2 h, another blood sample was obtained. The patients were on an ordinal dialysis diet for 6 months of the trial but did not take a special diet that determined the amount of protein and iron immediately prior to the iron absorption test. The patients did not fast before the test, but they did fast until the second sampling after the FCH dose. R-OIAT sampling was repeated thrice at M0, M3, and M6. Blood samples were centrifuged at  $1500 \times g$  for 10 min, and the serum was immediately frozen at -20 °C. Samples were shipped on dry ice to Kanazawa Medical University to determine serum iron, FTN, unsaturated iron-binding capacity (UIBC), and hepcidin-25 levels. Serum iron and UIBC levels were measured using colorimetry; TSAT was calculated using the following formula: serum iron/total iron-binding capacity  $\times$  100. The FTN levels were measured using a chemiluminescent enzyme immunoassay. Serum hepcidin-25 was measured using LC-MS/MS [38] at MCProt Biotechnology (Ishikawa, Japan), with a dynamic range of 0–1000 ng/mL. LC-MS/MS was performed using 4000 QTRAP (Applied Biosystems, Foster City, CA, USA) equipped with HPLC pump (Shimadzu Corp., Kyoto, Japan). ESA doses were calculated on each oral iron absorption trial day. Because patients were taking different ESAs (i.e., epoetin (IU), darbepoetin ( $\mu$ g), or epoetin beta pegol ( $\mu$ g)), their units were converted to international units (IUs) based on previously reported data [39]. The conversion for darbepoetin and epoetin beta pegol was based on reports that found that  $1 \mu g$  is equivalent to 200 IU [40]. The amount of ESAs was assessed as average weekly doses (IU/week).

### 4.3. Estimating Iron Absorption

The amount of iron absorbed after FCH administration ( $\Delta$ Fe2h) was determined by subtracting the serum iron concentration before administration from the serum iron concentration measured 2 h later according to previous studies [41]. In preliminary experiments,  $\Delta$ Fe2h ranged from 0 to 23 µg/dL in 36 control hemodialysis patients without FCH administration, and the median (inter-quartile range, IQR) of  $\Delta$ Fe2h was 0.5 (IQR: 0–7) µg/dL.

### 4.4. Statistical Analysis

Continuous variables were summarized as the mean and standard deviation. Categorical variables were described as the numbers and relative frequencies (%) of the subjects in each category. Iron variables were naturally log-transformed to maintain a normal distribution. Comparisons between patient groups were carried out using one-way analysis of variance (ANOVA) or repeated measures ANOVA with post hoc Bonferroni's multiple comparison tests. A two-way repeated measures ANOVA test (condition [750 mg vs. 1500 mg vs. 2250 mg of FCH]  $\times$  time [M0 vs. M3 vs. M6]) was used to analyze the effects of FCH on iron variables. Univariate correlations between variables were assessed using Pearson's correlation test. After adjusting for independent variables, GEEs were used to identify the determinants of iron absorption during each phase of FCH treatment: M0, M3, and M6; the B coefficients with their 95% CI and the corresponding p values < 0.05 were used to declare the determinants of iron absorption. Independent predictors of FTN were also assessed using GEEs. Differences in iron variables between the ranges of RBCs were compared using independent *t*-tests for parametric data. All p values were two-tailed, with a level of <0.05. Database construction and statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 24 (IBM SPSS Inc., Armonk, NY, USA).

**Author Contributions:** N.T. and Y.K. conceived the studies and obtained funding. All authors contributed to the design of the trials and were responsible for data collection. N.T. and Y.K. conceived the study and obtained funding. N.T. analyzed the data and wrote the first draft of the manuscript. Y.K. created all the figures. The corresponding author had full access to all data in the study and had the final responsibility for the decision to submit it for publication. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the Kanazawa Medical University grant, the Torii Pharmaceutical Co., Ltd. (Tokyo, Japan) grant (primary funding source), and the Japan Tobacco Inc. (Tokyo, Japan) grant. The funders had no role in the study's design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

**Institutional Review Board Statement:** This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Kanazawa Medical University Ethics Committee (No. M401, approved September 2016).

**Informed Consent Statement:** Informed consent was obtained from all individual participants included in the study. All participants provided written informed consent.

**Data Availability Statement:** Data is contained within the article. The data that support the findings of this study are available on request from the corresponding author, [N.T.]. The data are not publicly available due to their containing information that could compromise the privacy of research participants.

Acknowledgments: We would like to thank the participants and the participating nursing staff.

**Conflicts of Interest:** Tomosugi is a professor at Kanazawa Medical University and the president of Medical Care Proteomics Biotechnology Co., Ltd. However, this association did not alter the authors' adherence to all policies regarding the sharing of data. The authors have declared that no conflict of interest exist.

# References

- Fishbane, S.; Spinowitz, B. Update on anemia in ESRD and earlier stages of CKD: Core curriculum 2018. Am. J. Kidney Dis. 2018, 71, 423–435. [CrossRef]
- Besarab, A.; Coyne, D.W. Iron supplementation to treat anemia in patients with chronic kidney disease. *Nat. Rev. Nephrol.* 2010, 6, 699–710. [CrossRef]
- 3. Pergola, P.E.; Fishbane, S.; Ganz, T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. *Adv. Chronic Kidney Dis.* **2019**, *26*, 272–291. [CrossRef] [PubMed]
- 4. Yokoyama, K.; Akiba, T.; Fukagawa, M.; Nakayama, M.; Sawada, K.; Kumagai, Y.; Chertow, G.M.; Hirakata, H. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. *J. Ren. Nutr.* **2014**, *24*, 261–267. [CrossRef]
- 5. Lewis, J.B.; Sika, M.; Koury, M.J.; Chuang, P.; Schulman, G.; Smith, M.T.; Whittier, F.C.; Linfert, D.R.; Galphin, C.M.; Athreya, B.P.; et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. *J. Am. Soc. Nephrol.* **2015**, *26*, 493–503. [CrossRef]
- Umanath, K.; Jalal, D.I.; Greco, B.A.; Umeukeje, E.M.; Reisin, E.; Manley, J.; Zeig, S.; Negoi, D.G.; Hiremath, A.N.; Blumenthal, S.S.; et al. Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD. J. Am. Soc. Nephrol. 2015, 26, 2578–2587. [CrossRef] [PubMed]
- 7. Kühn, L.C. Iron regulatory proteins and their role in controlling iron metabolism. *Metallomics* 2015, 7, 232–243. [CrossRef]
- 8. Ramanathan, G.; Olynyk, J.K.; Ferrari, P. Diagnosing and preventing iron overload. *Hemodial. Int.* **2017**, *21* (Suppl. S1), S58–S67. [CrossRef] [PubMed]
- 9. Roe, M.A.; Collings, R.; Dainty, J.R.; Swinkels, D.W.; Fairweather-Tait, S.J. Plasma hepcidin concentrations significantly predict interindividual variation in iron absorption in healthy men. *Am. J. Clin. Nutr.* **2009**, *89*, 1088–1091. [CrossRef]
- 10. Honda, H.; Kobayashi, Y.; Onuma, S.; Shibagaki, K.; Yuza, T.; Hirao, K.; Yamamoto, T.; Tomosugi, N.; Shibata, T. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. *PLoS ONE* **2016**, *11*, e0151601. [CrossRef]
- 11. Pak, M.; Lopez, M.A.; Gabayan, V.; Ganz, T.; Rivera, S. Suppression of hepcidin during anemia requires erythropoietic activity. *Blood* 2006, *108*, 3730–3735. [CrossRef] [PubMed]
- 12. Gulec, S.; Anderson, G.J.; Collins, J.F. Mechanistic and regulatory aspects of intestinal iron absorption. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2014**, 307, G397–G409. [CrossRef]
- 13. Kautz, L.; Jung, G.; Valore, E.V.; Rivella, S.; Nemeth, E.; Ganz, T. Identification of erythroferrone as an erythroid regulator of iron metabolism. *Nat. Genet.* **2014**, *46*, 678–684. [CrossRef]
- 14. Li, H.; Ginzburg, Y.Z. Crosstalk between iron metabolism and erythropoiesis. Adv. Hematol. 2010, 2010, 605435. [CrossRef]
- 15. Verga Falzacappa, M.V.; Vujic Spasic, M.; Kessler, R.; Stolte, J.; Hentze, M.W.; Muckenthaler, M.U. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. *Blood* **2007**, *109*, 353–358. [CrossRef]
- Chaston, T.; Chung, B.; Mascarenhas, M.; Marks, J.; Patel, B.; Srai, S.K.; Sharp, P. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. *Gut* 2008, *57*, 374–382. [CrossRef] [PubMed]
- 17. Brasse-Lagnel, C.; Karim, Z.; Letteron, P.; Bekri, S.; Bado, A.; Beaumont, C. Intestinal DMT1 cotransporter is down-regulated by hepcidin via proteasome internalization and degradation. *Gastroenterology* **2011**, *140*, 1261–1271. [CrossRef]
- Hanudel, M.R.; Czaya, B.; Wong, S.; Rappaport, M.; Namjoshi, S.; Chua, K.; Jung, G.; Gabayan, V.; Qiao, B.; Nemeth, E.; et al. Enteral ferric citrate absorption is dependent on the iron transport protein ferroportin. *Kidney Int.* 2022, 101, 711–719. [CrossRef] [PubMed]
- 19. Nemeth, E.; Ganz, T. Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis. *Int. J. Mol. Sci.* **2021**, 22, 6493. [CrossRef]
- 20. Wintrobe, M.M. Chapter 2: The erythrocyte. In *Clinical Hematology*, 6th ed.; Wintrobe, M.M., Ed.; Lea & Febiger: Philadelphia, PA, USA, 1967; pp. 63–103.
- Vajpayee, N.; Graham, S.S.; Bem, S. Chapter 30: Basic examination of blood and bone marrow. In *Henry's Clinical Diagnosis and Management by Laboratory Methods*, 22nd ed.; McPherson, R.A., Pincus, M.R., Eds.; WB Saunders: Philadelphia, PA, USA, 2011; pp. 509–535.
- 22. Kawabata, H. Transferrin and transferrin receptors update. Free Radic. Biol. Med. 2019, 133, 46–54. [CrossRef]
- Eschbach, J.W.; Cook, J.D.; Scribner, B.H.; Finch, C.A. Iron balance in hemodialysis patients. Ann. Intern. Med. 1977, 87, 710–713. [CrossRef]
- 24. Camaschella, C.; Nai, A.; Silvestri, L. Iron metabolism and iron disorders revisited in the hepcidin era. *Haematologica* **2020**, *105*, 260–272. [CrossRef]
- Egrie, J.C.; Strickland, T.W.; Lane, J.; Aoki, K.; Cohen, A.M.; Smalling, R.; Trail, G.; Lin, F.K.; Browne, J.K.; Hines, D.K. Characterization and biological effects of recombinant human erythropoietin. *Immunobiology* 1986, 172, 213–224. [CrossRef] [PubMed]
- Kawabata, H.; Fleming, R.E.; Gui, D.; Moon, S.Y.; Saitoh, T.; O'Kelly, J.; Umehara, Y.; Wano, Y.; Said, J.W.; Koeffler, H.P. Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. *Blood* 2005, 105, 376–381. [CrossRef]
- 27. Daru, J.; Colman, K.; Stanworth, S.J.; De La Salle, B.; Wood, E.M.; Pasricha, S.R. Serum ferritin as an indicator of iron status: What do we need to know? *Am. J. Clin. Nutr.* **2017**, *106*, 1634S–1639S. [CrossRef] [PubMed]

- Babitt, J.L.; Eisenga, M.F.; Haase, V.H.; Kshirsagar, A.V.; Levin, A.; Locatelli, F.; Małyszko, J.; Swinkels, D.W.; Tarng, D.C.; Cheung, M.; et al. Controversies in optimal anemia management: Conclusions from a kidney disease: Improving Global Outcomes (KDIGO) Conference. *Kidney Int.* 2021, 99, 1280–1295. [CrossRef] [PubMed]
- Tsubakihara, Y.; Nishi, S.; Akiba, T.; Hirakata, H.; Iseki, K.; Kubota, M.; Kuriyama, S.; Komatsu, Y.; Suzuki, M.; Nakai, S.; et al. 2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease. *Ther. Apher. Dial.* 2010, 14, 240–275. [CrossRef]
- Soe-Lin, S.; Apte, S.S.; Andriopoulos, B., Jr.; Andrews, M.C.; Schranzhofer, M.; Kahawita, T.; Garcia-Santos, D.; Ponka, P. Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. *Proc. Natl. Acad. Sci. USA* 2009, 106, 5960–5965. [CrossRef]
- Zhang, D.L.; Ghosh, M.C.; Ollivierre, H.; Li, Y.; Rouault, T.A. Ferroportin deficiency in erythroid cells causes serum iron deficiency and promotes hemolysis due to oxidative stress. *Blood* 2018, 132, 2078–2087. [CrossRef]
- 32. Coffey, R.; Ganz, T. Iron homeostasis: An anthropocentric perspective. J. Biol. Chem. 2017, 292, 12727–12734. [CrossRef]
- 33. Santini, V.; Girelli, D.; Sanna, A.; Martinelli, N.; Duca, L.; Campostrini, N.; Cortelezzi, A.; Corbella, M.; Bosi, A.; Reda, G.; et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. *PLoS ONE* 2011, 6, e23109. [CrossRef] [PubMed]
- Tantiworawit, A.; Khemakapasiddhi, S.; Rattanathammethee, T.; Hantrakool, S.; Chai-Adisaksopha, C.; Rattarittamrong, E.; Norasetthada, L.; Charoenkwan, P.; Srichairatanakool, S.; Fanhchaksai, K. Correlation of hepcidin and serum ferritin levels in thalassemia patients at Chiang Mai University Hospital. *Biosci. Rep.* 2021, 41, BSR20203352. [CrossRef]
- 35. Daimon, S. Efficacy for anaemia and changes in serum ferritin levels by long-term oral iron administration in haemodialysis patients. *Ther. Apher. Dial.* **2019**, *23*, 444–450. [CrossRef] [PubMed]
- Rausa, M.; Pagani, A.; Nai, A.; Campanella, A.; Gilberti, M.E.; Apostoli, P.; Camaschella, C.; Silvestri, L. Bmp6 expression in murine liver non parenchymal cells: A mechanism to control their high iron exporter activity and protect hepatocytes from iron overload? *PLoS ONE* 2015, 10, e0122696. [CrossRef]
- Kawabata, H.; Usuki, K.; Shindo-Ueda, M.; Kanda, J.; Tohyama, K.; Matsuda, A.; Araseki, K.; Hata, T.; Suzuki, T.; Kayano, H.; et al. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. *Int. J. Hematol.* 2019, 110, 533–542. [CrossRef] [PubMed]
- Murao, N.; Ishigai, M.; Yasuno, H.; Shimonaka, Y.; Aso, Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. *Rapid Commun. Mass Spectrom.* 2007, 21, 4033–4038. [CrossRef] [PubMed]
- Aljama, P.; Bommer, J.; Canaud, B.; Carrera, F.; Eckardt, K.U.; Hörl, W.H.; Krediet, R.T.; Locatelli, F.; Macdougall, I.C.; Wikström, B. Practical guidelines for the use of NESP in treating renal anaemia. *Nephrol. Dial. Transplant.* 2001, 16 (Suppl. S3), 22–28. [CrossRef]
- Carrera, F.; Lok, C.E.; de Francisco, A.; Locatelli, F.; Mann, J.F.; Canaud, B.; Kerr, P.G.; Macdougall, I.C.; Besarab, A.; Villa, G.; et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycolepoetin beta versus darbepoetin alfa administered monthly: A randomized comparative trial. *Nephrol. Dial. Transplant.* 2010, 25, 4009–4017. [CrossRef]
- Conway, R.E.; Geissler, C.A.; Hider, R.C.; Thompson, R.P.; Powell, J.J. Serum iron curves can be used to estimate dietary iron bioavailability in humans. J. Nutr. 2006, 136, 1910–1914. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.